BioHarvest Sciences Inc. (BHST) Q2 2025 Earnings Call Transcript
- BioHarvest Sciences Inc. (NASDAQ:BHST ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Bar Dichter - Chief Financial Officer Ilan Sobel - Chief Executive Officer Conference Call Participants Amit Dayal - H.C. Wainwright & Co, LLC, Research Division Anthony V.
- 08/11/2025
|
BioHarvest Sciences Q2 revenue jumps on VINIA growth
- BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 41% rise in second-quarter revenue, driven by growth in its VINIA product line and contributions from its contract development and manufacturing (CDMO) business. Revenue for the quarter ended June 30 rose to $8.5 million from $6 million a year earlier, in line with the company's guidance.
- 08/11/2025
|
BioHarvest Sciences Reports Second Quarter 2025 Financial Results
- Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales Rehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.
- 08/11/2025
|
BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time
- Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025. Management will host an investor conference call and webcast at 8:00 a.m.
- 08/04/2025
|
BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?
- BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 07/24/2025
|
BioHarvest Sciences to Present at Canaccord Genuity 45th Annual Growth Conference on August 12-14, 2025
- Rehovot, Israel--(Newsfile Corp. - July 23, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the Canaccord Genuity 45th Annual Growth Conference taking place on August 12-14, 2025 in Boston, Massachusetts. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the event and will host a live BioHarvest Sciences corporate presentation as shown below.
- 07/23/2025
|
BioHarvest Sciences launches Informed Sport-certified daily chew - ICYMI
- BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel talked with Proactive about the company's newest addition to its Vinia product line, a daily “2X formula” chew, specifically designed for athletes and highly active consumers. The chew delivers 12mg of Piceid Resveratrol, doubling the dose found in the original capsule format.
- 06/07/2025
|
BioHarvest Sciences launches Informed Sport-certified VINIA DailyChews 2X Formula
- BioHarvest Sciences Inc. (NASDAQ:BHST) has launched a new product tailored to athletes and individuals with active lifestyles called VINIA DailyChews 2X Formula. The developer of botanical-based wellness products using its proprietary Botanical Synthesis said this new product is now available for purchase in a 30-count pack through VINIA.com.
- 06/04/2025
|
BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
- Rehovot, Israel--(Newsfile Corp. - June 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of VINIA® DailyChews 2X Formula, a first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. VINIA® DailyChews 2X Formula are now available for purchase in a 30-count pack on VINIA.com.
- 06/04/2025
|
What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'
- BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 06/03/2025
|
BioHarvest enters fragrance industry with AI edge - ICYMI
- BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week announced a new contract targeting the plant-based fragrance compound market, using its proprietary botanical synthesis platform. CEO Ilan Sobel said the contract focuses on a rare plant under threat from overharvesting and habitat loss.
- 05/23/2025
|
BioHarvest inks fragrance compound deal in move into multi-billion-dollar scents market
- BioHarvest Sciences Inc. (NASDAQ:BHST) said it has signed a contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking the company's entry into the multi-billion-dollar fragrance and scents industry. The contract, with an undisclosed commercial partner, targets the development of a compound derived from a threatened plant species facing overharvesting and habitat loss.
- 05/21/2025
|
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
- First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
- 05/21/2025
|
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI
- BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in the development of plant-derived biological materials for use in approved drugs.
- 05/17/2025
|
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
- BioHarvest Sciences Inc. (NASDAQ:BHST ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Amit Dayal - H.C. Wainwright Susan Anderson - Canaccord Genuity Nicholas Sherwood - Maxim Group Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences First Quarter 2025 Corporate Update Conference Call.
- 05/15/2025
|
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
- BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
- 05/15/2025
|
BioHarvest Sciences Q1 revenue jumps on VINIA growth
- BioHarvest Sciences Inc. (NASDAQ:BHST), a developer of plant-based biologics, reported a 47% year-over-year jump in first-quarter revenue on Wednesday, driven by strong demand for its flagship VINIA line of wellness products. Revenue for the quarter ended March 31 rose to $7.9 million, topping internal forecasts, as gross margins expanded by 227 basis points to 58.5%.
- 05/15/2025
|
BioHarvest Sciences Reports First Quarter 2025 Financial Results
- First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management Guidance Rehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter & Subsequent 2025 Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.
- 05/15/2025
|
Goldman Sachs hikes growth forecasts, predicts Fed will not cut rates til December
- Goldman Sachs has upped its US growth forecasts, following the Trump administration's agreement of a 90-day pause on tariffs with China at the start of the week. The agreement will leave the US and China with 2025 tariff increases of 30% and 15%, respectively. "While we had expected a de-escalation, the rate is lower than the +54pp tariff hike we had penciled into our baseline," the Wall Street bank said in a note. "We expect this move to leave the US effective tariff rate increase at +13pp, assuming that likely sectoral tariffs on pharmaceuticals and semiconductors take effect, slightly below our previous assumption of +15pp." In light of the pause and the "meaningful easing in financial conditions" over the last month, Goldman has hiked its 2025 growth forecast by 0.5 percentage points to 1% in the fourth quarter, and reduced its 12-month recession odds to 35%. "Under our new economic baseline, the rationale for rate cuts shifts from insurance to normalization as growth remains somewhat firmer, the unemployment rate rises by somewhat less, and the urgency for policy support is reduced." Goldman said it now expects the Federal Reserve to begin a series of three cuts in December, having previously predicted cuts would come in July. And it expects the Fed to implement the cuts at every other meeting rather than sequentially. BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product. Stage 1 involved sourcing the required plants and successfully isolating, mirroring, magnifying, and multiplying the target plant cells using BioHarvest’s proprietary platform. In Stage 2, the company will deliver a sufficient amount of biomass for testing and optimize growing conditions in liquid media. If successful, this will lead to small- and medium-scale production, with the potential to reach commercial manufacturing volumes. Ilan Sobel, BioHarvest Sciences CEO, noted that this marks the first CDMO project to advance to Stage 2. “This milestone validates the versatility of our Botanical Synthesis platform to deliver scalable, cost-effective alternatives to traditional compound sourcing,” Sobel said. “Stage One success also reinforces our position as a trusted partner for pharma, nutrition, and nutraceutical players seeking next-generation plant-based solutions. We expect this achievement to accelerate additional CDMO opportunities as we help shape the future of therapeutics." Dr Zaki Rakib, president of BioHarvest Sciences’ CDMO Division, highlighted that Stage 1 carries the highest technical risk, and completing it proves that the company’s platform can address a broad range of molecule families. “Stage 2 will focus on scaling biomass and refining compound concentration, and carries a much higher probability of success. Importantly, this project sharpened our analytical capabilities and validated our in-house AI tools, which will now support all future CDMO engagements,” Dr Rakib said.
- 05/13/2025
|
BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stage
- BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product.
- 05/12/2025
|
BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
- Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. Stage 1 of the contract, launched in early 2024, focused on sourcing the required plants to develop a compound used to produce an approved drug product.
- 05/12/2025
|
BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/08/2025
|
BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time
- Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. Management will host an investor conference call and webcast at 4:30 p.m.
- 05/01/2025
|
BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
- BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 04/15/2025
|
BioHarvest CEO talks Nasdaq uplisting, profit targets - ICYMI
- BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week reported its financial results for 2024, showing a 99.00% year-over-year increase in revenue to 25.20 million US dollars. The company said fourth-quarter revenue was 7.30 million US dollars, up 62.00% compared to the prior year, and ahead of previously issued guidance.
- 04/05/2025
|
BioHarvest shares rise after Q4 results show strong demand for VINIA products
- BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 62% year-over-year increase in fourth-quarter revenue, reaching $7.3 million, as the biotechnology company saw strong demand for its VINIA product lines and expanded its contract development and manufacturing organization (CDMO) services. Full-year revenue nearly doubled to $25.2 million, with gross margins improving by 1,000 basis points to 55%.
- 04/01/2025
|
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call Transcript
- BioHarvest Sciences Inc. (NASDAQ:BHST ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Anthony Vendetti - Maxim Group Amit Dayal - H.C. Wainwright Hunter Diamond - Diamond Equity Research Susan Anderson - Canaccord Operator Greetings, and welcome to the BioHarvest Sciences Fourth Quarter 2024 Corporate Update Conference Call.
- 03/31/2025
|
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
- BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.70 per share a year ago.
- 03/31/2025
|
BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results
- Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million CDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based Sweeteners Rehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Subsequent Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.
- 03/31/2025
|
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
- BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/17/2025
|
BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time
- Rehovot, Israel--(Newsfile Corp. - March 17, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, March 31, 2025. Management will host an investor conference call and webcast at 4:30 p.m.
- 03/17/2025
|
BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.
- 03/06/2025
|
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
- Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest's Future Olive Cell Product Targeting Liver Health Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in vitro' test results for the Company's proprietary new Olive Cell compound, which showed reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (NAFLD), which affects 30-40% of U.S. adults*.
- 03/04/2025
|
BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD
- Commercial success of VINIA validates the power of BioHarvest's patented Botanical Synthesis technology to produce valuable plant-based Compounds at industrial scale Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 18, 2025) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that its Red Grape Cell composition - known commercially as VINIA® - has now exceeded $50 Million USD in cumulative sales with the vast majority of sales occurring since launching in the US less than 4 years ago. VINIA®, a red grape cell-based supplement, is produced by BioHarvest's proprietary Botanical Synthesis platform technology.
- 02/18/2025
|
BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the WeBull Consumer Stocks Virtual Webinar taking place on February 18, 2025. CEO Ilan Sobel is scheduled to present at the event.
- 02/12/2025
|
BioHarvest Sciences appoints veteran technology leader to board of directors
- BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) has announced the appointment of seasoned technology executive Sharon Malka as an independent director of the company. Malka brings extensive leadership experience to BioHarvest, with a background spanning international healthcare and technology companies.
- 01/22/2025
|
BioHarvest Announces Appointment of Sharon Malka to Board of Directors
- Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest.
- 01/22/2025
|
BioHarvest Sciences positioned for ‘legacy year' in 2025, building on momentum with new innovations and strategic collaborations
- BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) is poised to capitalize on key trends shaping the health and wellness industry in 2025, including a growing focus on sustainability, longevity-driven health solutions, and plant-based innovation. “The notions of sustainability, longevity, and the recognition of the power that exists in plants from consumers and industry are three critical trends that are really driving tailwinds,” Ilan Sobel, BioHarvest Sciences CEO, told Proactive.
- 01/20/2025
|
BioHarvest Sciences CEO reflects on transformative 2024, outlines vision for future growth
- BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) CEO Ilan Sobel has reflected on 2024 as “a year of transformation and growth” for the company. In a letter to shareholders, Sobel highlighted the launch of the company's Contract Development and Manufacturing Organization (CDMO) Services division as “the most transformational change in 2024” for BioHarvest.
- 01/08/2025
|
BioHarvest Issues Shareholder Letter and Provides Corporate Update
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 8, 2025) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel. Dear Fellow Shareholders, 2024 can be summarized as a year of transformation and growth for BioHarvest, where we introduced our new CDMO Services division - anchored by a partnership with a tier-1 food ingredients producer, Tate & Lyle.
- 01/08/2025
|
BioHarvest Sciences CEO discusses Tate & Lyle partnership - ICYMI
- BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) this week announced a significant move for the company, a partnership with Tate & Lyle to develop plant-based sweeteners. The collaboration aims to create botanical, plant-derived sweeteners that are sustainable, low-calorie, and offer superior taste.
- 12/14/2024
|
BioHarvest Sciences partners with Tate & Lyle to advance plant-based sweeteners
- BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) announced it has partnered with Tate & Lyle PLC (LSE:TATE) to develop proprietary plant-based molecules for food and beverage ingredients. The partnership will focus on developing botanical sweeteners that aim to provide a sugar-like taste without an aftertaste.
- 12/11/2024
|
Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients Through Botanical Synthesis Technology
- New collaboration to pioneer next generation of plant-based ingredients for healthier food and beverages London, United Kingdom and Vancouver, British Columbia--(Newsfile Corp. - December 11, 2024) - Tate & Lyle PLC ('Tate & Lyle'), a world leader in ingredient solutions for healthier and tastier food and beverages, and BioHarvest Sciences (NASDAQ: BHST) (CSE: BHSC) ('BioHarvest'), leaders in Botanical Synthesis, announce a pioneering new partnership to develop the next-generation of proprietary plant-based molecules to address increasing consumer desire for affordable, nutritious and more sustainable plant-derived food and beverage ingredients. BioHarvest's proven Botanical Synthesis platform produces non-GMO plant-derived ingredients in a more sustainable and economically viable way, helping to scale up the production of highly beneficial botanical ingredients.
- 12/11/2024
|
BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript
- BioHarvest Sciences Inc. (NASDAQ:BHST ) Q3 2024 Earnings Conference Call November 25, 2024 4:30 PM ET Company Participants Justin Meiklem - IR Ilan Sobel - CEO Bar Dichter - CFO Zaki Rakib - President of Botanical Synthesis CDMO Business Unit Conference Call Participants Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 11/25/2024
|
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
- BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago.
- 11/25/2024
|
BioHarvest Sciences reports increased revenues, profits for Q3
- BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) reported robust financial performance for the third quarter ending September 30, 2024. The company achieved a 101% year-over-year revenue increase to $6.5 million, surpassing management's guidance.
- 11/25/2024
|
BioHarvest Sciences Reports Third Quarter 2024 Financial Results
- Third Quarter 2024 Revenue Increased 101% Year-over-Year to Over $6.5 Million, Exceeding Management Guidance Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.
- 11/25/2024
|
BioHarvest Sciences launches VINIA SuperFood Teas
- BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has expanded its product offerings with the launch of VINIA SuperFood Functional Teas, marking a strategic move into the $3.3 billion North American functional tea market. The new line features four premium blends: Black Tea, Green Tea, Matcha Green Tea, and Cranberry Hibiscus Herbal Tea, each infused with piceid resveratrol, the active ingredient from the company's clinically validated VINIA supplements.
- 11/25/2024
|
BioHarvest Launches VINIA SuperFood Functional Tea Line
- Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood Tea Infused with Piceid Resveratrol Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 25, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced the launch of its highly anticipated VINIA® infused teas - a line of SuperFood functional teas that deliver the same clinically validated benefits as the successful VINIA® supplements. This launch further demonstrates the potential of VINIA's lifetime value across multiple consumer verticals.
- 11/25/2024
|
BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 21, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place on December 3, 2024. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the event and will host a presentation for in-person attendees.
- 11/21/2024
|
BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 P.M. Eastern Time
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 18, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2024 after market close on Monday, November 25, 2024. Management will host an investor conference call at 4:30 p.m.
- 11/18/2024
|
BioHarvest shares rise in Nasdaq debut
- BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) began trading on the Nasdaq Global Market on Tuesday under the ticker symbol "BHST." Shares of the company gained nearly 5% in early morning trading, reaching US$6 just after the opening bell.
- 11/12/2024
|
BioHarvest Sciences Begins Trading on the Nasdaq Global Market
- Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's shares will begin trading on the Nasdaq Global Market ("Nasdaq") at the opening of the U.S. market today under the new ticker symbol "BHST". The Company's common shares will continue to trade on the Canadian Securities Exchange ("CSE").
- 11/12/2024
|
